Olympus Corp. · TSE:7733
Olympus — 39th Annual J.P. Morgan Healthcare Conference (January 2021)
26 slides from Olympus's conference presentation, Jan 14, 2021
Slide 1: 39th annual J.P. Morgan healthcare conference
39th annual J.P. Morgan healthcare conference Olympus Corporation | Director, Representative Executive Officer, President and CEO | Yasuo Takeuchi | 14 January, 2021
Slide 2: Disclaimer
Disclaimer This material contains forward-looking statements that reflect management’s current views, plans, and expectations based on information available at the time of preparation. These forward-looking statements are not guarantees of future performance and involve known and unknown risks, un
Slide 3: We're Olympus; Accelerating transformations; Strengthening Medical Footprint
01 We’re Olympus 02 Accelerating transformations 03 Strengthening Medical Footprint
Slide 4: We're Olympus
OLYMPUS O 1 We’re Olympus
Slide 5: Our Philosophy
Our Philosophy OUR PURPOSE Making people’s lives healthier, safer and more fulfilling In line with our Corporate Philosophy, we are evolving our corporate culture to be competitive and performance-driven and focusing on creating value to our customers Page 5 No data copy / No data transfer permitted
Slide 6: Revenue by Business Divisions (Continuing Operation)
Revenue by Business Divisions*（Continuing Operation） 13.9% Scientific Solutions 56.4% Endoscopic Solutions 28.6% FY2020** Therapeutic Solutions *The closing of divestiture of imaging business was completed on January 1, 2021 **Figures are before the audit Page 6 No data copy / No data transfer permi
Slide 7: We Are Committed to Deliver Ambitious Target
We Are Committed to Deliver Ambitious Target Sustain 5-6% growth annually Our aspiration is to become a globally-leading medtech company contributing to Deliver >20% consolidated people’s lives by delivering corporate operating margin* innovative solutions that benefit patients, healthcare professio
Slide 8: Accelerating Transformations
02 Accelerating Transformations
Slide 9: We are Walking the Talk
We are Walking the Talk Accelerating transformations to become a leading global medtech company Divestiture of Imaging Business Achieved Significant SG&A efficiency improvements Transforming to become Purpose-Driven Organization Strengthening global and med-tech professional density Long-waited laun
Slide 10: We are Walking the Talk
We are Walking the Talk Accelerating transformations to become a leading global medtech company Divestiture of Imaging Business Achieved Significant SG&A efficiency improvements Transforming to become Purpose-Driven Organization Strengthening global and med-tech professional density Long-waited laun
Slide 11: Divestiture of Imaging Business
Divestiture of Imaging Business Focusing on investments in corporate resources for our growth area of medical Completed divestiture of imaging business on Jan.1, 2021 Dec. 31, 2020 Jan.1, 2021 Endoscopic Solutions Endoscopic Solutions Therapeutic Solutions Therapeutic Solutions Scientific Solution
Slide 12: Achieved Significant SG&A Efficiency Improvements
Achieved Significant SG&A Efficiency Improvements ¥32.5 billion reduction (7% decrease) from FY2019 Continuing operation + Discontinued operation Continuing operation (Billions of yen) (Billions of yen) - ¥32.5 bn - ¥15.2 bn 426.6 437.5 405.0 381.2 366.0 FY2018 FY2019 FY2020 FY2020* FY2021 (Forecast
Slide 13: Transforming to become Purpose-Driven Organization
Transforming to become Purpose-Driven Organization Implementation of the Career Support for external opportunity in Japan: Streamlining the Organization Pre-Requisite for Success Live by Our Purpose Diversity and Open Culture Agility to Respond Ability to Compete Page 13 No data copy / No da
Slide 14: Strengthening Global and Medtech Professional Density
Strengthening Global and Medtech Professional Density 経営戦略に沿った取締役構成とグローバル専門人材登用の促進 Bringing More Global and Diversity Perspective Appointing and assigning talent regardless of Develop medical affairs and QA/RA nationality, age, or gender Percentage changes of non-Japanese professionals in leadership
Slide 15: Strengthening Medical Footprint
03 Strengthening Medical Footprint
Slide 16: We are Walking the Talk
We are Walking the Talk Accelerating transformations to become a leading global medtech company Divestiture of Imaging Business Achieved Significant SG&A efficiency improvements Transforming to become Purpose-Driven Organization Strengthening global and med-tech professional density Long-waited laun
Slide 17: Medical needs remain unchanged
Medical needs remain unchanged Early diagnosis and minimally invasive treatment are our strengths Gastrointestinal Magnifying endoscopes Biopsy forceps Surgical endoscopy Surgical energy devices endoscopy systems Ultrasound endoscopes Cytology brushes Endotherapy devices systems Detection Diagnosis
Slide 18: Key Product Catalysts: Endoscopic Solutions
Key Product Catalysts: Endoscopic Solutions (As of Dec.31, 2020) Corporate Strategy of ESD : Further strengthen leadership in endoscopy Maintain leadership in Complement our portfolio with conventional endoscopy single-use endoscopes through continued innovation to provide a comprehensive set of pro
Slide 19: Strengthen Leadership in Endoscopy with EVIS X1
Strengthen Leadership in Endoscopy with EVIS X1 Long-Waited New Generation System to Drive Sales 70,000 units Potential for replacing the previous model* *Unit sales of CV-190 and CV-290 Page 19 No data copy / No data transfer permitted
Slide 20: Key Product Catalysts: Therapeutic Solutions
Key Product Catalysts: Therapeutic Solutions (As of Dec. 31, 2020) Corporate Strategy of TSD : Focus and scale our TSD business GI endotherapy Urology Respiratory endotherapy Expand and accelerate Establish leadership in Strengthen leadership by portfolio in existing product BPH and enhance capturin
Slide 21: Strategic Acquisition of Arc Medical Design Limited
Strategic Acquisition of Arc Medical Design Limited Contribute to maintain visibility in colonoscopy and endoscopic polypectomy ENDOCUFF VISION™ Adenoma Detection Rate Increases the adenoma detection rate by up to 35% +11% 11% (result of meta-analysis) 30% for every 1,000 patients screened, it is es
Slide 22: Page 22 No data copy / No data transfer permitted
Page 22 No data copy / No data transfer permitted
Slide 23: Grow Respiratory Portfolio with Acquisition of Veran Medical Technologies
Grow Respiratory Portfolio with Acquisition of Veran Medical Technologies Lung cancer affects the highest number of cancer patients and is the leading cause of cancer-related deaths globally* >70% Our market share of bronchoscope Bronchoscope Electromagnetic Navigation System *WHO data: https://www.
Slide 24: Page 24 No data copy / No data transfer permitted
Page 24 No data copy / No data transfer permitted
Slide 25: Our Journey to Transform into a Truly Global Medtech Company
Our Journey to Transform into a Truly Global Medtech Company FY2023 FY2022 FY2021 Committed to Corporate Reforms Return to Growth and Continue Transformation Deliver >20% Introduction of EVIS X1 in U.S. and sales consolidated corporate Focus the corporate portofolio expansion operating margin*
Slide 26: OLYMPUS
OLYMPUS
Olympus — 39th Annual J.P. Morgan Healthcare Conference (January 2021) on 6ix